The ongoing Phase I trial sponsored by the National Cancer Institute (NCI) evaluates the safety and efficacy of cirtuvivint as a monotherapy and in combination with ASTX727 for treating relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). Given the high unmet medical need in these indications, successful outcomes could position cirtuvivint as a competitive option in a market with limited effective therapies. The trial's focus on both monotherapy and combination therapy may enhance its commercial viability, particularly if it demonstrates improved safety and efficacy profiles compared to existing treatments. Stakeholders should monitor enrollment and preliminary efficacy data closely, as these will inform future development strategies and potential partnerships.